0001144204-18-064217.txt : 20181212
0001144204-18-064217.hdr.sgml : 20181212
20181212131538
ACCESSION NUMBER: 0001144204-18-064217
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181203
FILED AS OF DATE: 20181212
DATE AS OF CHANGE: 20181212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Paley Jeffrey
CENTRAL INDEX KEY: 0001595327
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38114
FILM NUMBER: 181230563
MAIL ADDRESS:
STREET 1: C/O RETROPHIN INC., 777 THIRD AVENUE
STREET 2: 22ND FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
FORMER NAME:
FORMER CONFORMED NAME: Paley Jeffery
DATE OF NAME CHANGE: 20131224
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVENUE THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001644963
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474113275
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 GANSEVOORT STREET
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: 781-652-4500
MAIL ADDRESS:
STREET 1: 2 GANSEVOORT STREET
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
4
1
tv508813_form4.xml
FORM 4
X0306
4
2018-12-03
0
0001644963
AVENUE THERAPEUTICS, INC.
ATXI
0001595327
Paley Jeffrey
C/O AVENUE THERAPEUTICS, INC.
2 GANSEVOORT STREET, 9TH FLOOR
NEW YORK
NY
10014
1
0
0
0
Common Stock
2018-12-03
4
P
0
10000
5.4754
A
74663
D
Common Stock
2018-12-10
4
P
0
5000
4.76
A
79663
D
Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on December 3, 2018 was $5.4734 to $5.4774. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
Includes 64,663 shares of restricted stock.
/s/ Lucy Lu, M.D., Attorney-in-Fact
2018-12-12